

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

CMT167

RRID:CVCL_2405

Type: Cell Line

Proper Citation

Ximbio Cat# 151448, RRID:CVCL_2405

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2405

Proper Citation: Ximbio Cat# 151448, RRID:CVCL_2405

Description: Cell line CMT167 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Adenocarcinoma of the mouse pulmonary system

Defining Citation: [PMID:6324836](#), [PMID:9347924](#), [PMID:19003861](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: CMT167

Synonyms: CMT-167, CMT 167

Cross References: BTO:BTO_0005821, CancerTools:151448, ECACC:10032302, Wikidata:Q54813840, Ximbio:151448

ID: CVCL_2405

Vendor: Ximbio

Catalog Number: 151448

Hierarchy: cvcl_2406

Record Creation Time: 20220427T215511+0000

Record Last Update: 20260829T231854+0000

Ratings and Alerts

No rating or validation information has been found for CMT167.

No alerts have been found for CMT167.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wu S, et al. (2026) Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer. Cancer letters, 657, 218702.

Shang X, et al. (2026) Dual PD-1/IL-2R?? targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. Cancer research, 86(6), 1414.

Li C, et al. (2026) New Insights Into the Role of Polo-Like Kinase 3 in Lung Tumorigenesis. Journal of cellular biochemistry, 127(2), e70084.

Wang Y, et al. (2026) Targeting SERPINE1 enhances PD-1 blockade response by modulating macrophage infiltration and polarization through the STAT3-CCL2 axis in non-small cell lung cancer. International immunopharmacology, 178, 116577.

Suzuki S, et al. (2026) Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance. Cancer immunology research, 14(7), 1172.

Pedrosa AR, et al. (2025) Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential. The Journal of pathology, 266(4-5), 405.

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. Cell reports. Medicine, 6(11), 102434.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. Cell, 188(26), 7591.

Kitajima S, et al. (2022) MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer cell, 40(10), 1128.

Chen X, et al. (2022) CYP4F2-Catalyzed Metabolism of Arachidonic Acid Promotes Stromal Cell-Mediated Immunosuppression in Non-Small Cell Lung Cancer. *Cancer research*, 82(21), 4016.

Krache A, et al. (2021) Preclinical Pharmacokinetics and Dosimetry of an ^{89}Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model. *Frontiers in medicine*, 8, 741855.